Somatostatin vs Lanreotide
The brake on the growth-hormone axis — and much else. A depot somatostatin analog, similar in action to octreotide. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Somatostatin SST | Lanreotide | |
|---|---|---|
| Also known as | — | Somatuline |
| Type | Endogenous | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Cyclic peptide (14 and 28 aa forms) | Somatostatin analog (cyclic octapeptide) |
| Receptor | Somatostatin receptors SSTR1–SSTR5 | Somatostatin receptors (SSTR2 and SSTR5 preferential) |
| Molecular weight | ~1,637.9 Da | ~1,096.3 Da |
| Half-life | depot-dominant (autogel acts over weeks) | |
| Based on | Native hormone | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Somatostatin and Lanreotide?
- Somatostatin is an endogenous hormone; Lanreotide is an engineered analog based on Somatostatin. Somatostatin signals at Somatostatin receptors SSTR1–SSTR5; Lanreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential).
- How do the half-lives of SST and Lanreotide compare?
- The reported circulating half-life of Somatostatin is ~1–3 min (very short); Lanreotide is depot-dominant (autogel acts over weeks). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Lanreotide vs Somatostatin. Or open the interactive comparison tool to add more molecules.